HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

May 29, 2024 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical and maintained a $3 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst suggests positive sentiment and confidence in Icecure Medical's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100